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Abstract
Background: In Tanzania, routine individual-level testing for HIV drug resistance (HIVDR) using laboratory genotyping
and phenotyping is not feasible due to resource constraints. To monitor the prevention or emergence of HIVDR at a
population level, WHO developed generic strategies to be adapted by countries, which include a set of early warning
indicators (EWIs).
Methods: To establish a baseline of EWIs, we conducted a retrospective longitudinal survey of 35 purposively
sampled care and treatment clinics in 17 regions of mainland Tanzania. We extracted data relevant for four
EWIs (ART prescribing practices, patients lost to follow-up 12 months after ART initiation, retention on first-line
ART at 12 months, and ART clinic appointment keeping in the first 12 months) from the patient monitoring
system on patients who initiated ART at each respective facility in 2010. We uploaded patient information into
WHO HIVResNet excel-based tool to compute national and facility averages of the EWIs and tested for associations
between various programmatic factors and EWI performance using Fisher’s Exact Test.
Results: All sampled facilities met the WHO EWI target (100%) for ART prescribing practices. However, the national
averages for patients lost to follow-up 12 months after ART initiation, retention on first-line ART at 12 months, and ART
clinic appointment keeping in the first 12 months fell short, at 26%, 54% and 38%, respectively, compared to the WHO
targets ≤ 20%, ≥ 70%, and ≥ 80%. Clinics with fewer patients lost to follow-up 12 months after ART initiation and more
patients retained on first-line-ART at 12 months were more likely to have their patients spend the longest time in the
facility (including wait-time and time with providers), (p = 0.011 and 0.007, respectively).
Conclusion: Tanzania performed very well in EWI 1a, ART prescribing practices. However, its performance in other
three EWIs was far below the WHO targets. This study provides a baseline for future monitoring of EWIs in Tanzania
and highlights areas for improvement in the management of ART patients in order not only to prevent emergence of
HIVDR due to programmatic factors, but also to improve the quality of life for ART patients.
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Background
Antiretroviral therapy (ART) extends the lives of persons
living with HIV and AIDS and improves the quality of their
lives [1,2]. The rapid increase in ART coverage in low- and
middle-income countries, especially in Sub-Saharan Africa,
has also led to a clear decline in premature mortality [3,4].
ART, however, is not without complications, and subopti-
mal adherence can lead to therapeutic failure and the devel-
opment of antiretroviral resistance [2]. The development of
resistance requires changes in ART regimens with limited
therapeutic choices each time resistance occurs. Addition-
ally, individuals with drug-resistant HIV strains can trans-
mit them to infants or sexual and needle-sharing partners,
leading to infections that are already resistant to first-line
therapy and more difficult to treat [2].
In Tanzania, like most low-income country settings, rou-
tine individual-level testing for HIV drug resistance (HIVDR)
using laboratory genotyping and phenotyping is not feasible
due to resource constraints [5,6]. To monitor the appear-
ance of HIVDR at the population level, the World Health
Organization (WHO) developed a generic protocol for each
country to adapt based on the routine patient monitoring
system (PMS) in order to monitor and mitigate HIVDR [5].
The protocol focuses on eight elements: (i) creating an
HIVDR technical working group to develop and implement
the strategy, (ii) monitoring HIVDR early warning indica-
tors (EWIs) at ART sites, (iii) conducting sentinel monitor-
ing of HIVDR during treatment, (iv) conducting HIVDR
threshold surveys to assess the incidence of transmitted
HIVDR, (v) establishing an HIVDR database, (vi) designat-
ing an in-country or regional WHO-accredited HIVDR
genotyping laboratory, (vii) conducting a national-level
annual HIVDR situation review and making recommenda-
tions and (viii) the production of an annual report con-
taining evidence-based recommendations to minimize the
emergence and transmission of HIVDR. The EWIs, in par-
ticular, are attractive for ongoing monitoring because sali-
ent data can be retrieved from national ART PMSs [7], at
relatively low cost and quicker than the laboratory based
assays for the assessment of HIVDR mutations.
A limited number of studies are available from Africa that
assesses EWI performance [6,8-11], and none from Tanzania.
Furthermore, we could not find any studies that attempt to
use programmatic factors as predictors for EWI success.
Using four indicators that could be captured using the exist-
ing PMS, we undertook a baseline facility-level survey to a)
ascertain Tanzanian national performance against WHO
targets for four HIVDR EWIs and b) determine the corre-
lates of achievements or failures in reaching the targets.
Methods
Overall study design
We conducted a retrospective longitudinal survey in 35
purposively sampled care and treatment clinics (CTCs)
of patient cohorts who initiated ART in those facilities
in 2010.
Setting
The Tanzanian health system is comprised of referral
hospitals, regional hospitals, district hospitals, health
centres and dispensaries. Dispensaries serve as the main
point of care, larger health centres provide more com-
plex treatment including inpatient care, and district and
regional hospitals are equipped for surgery and referral-
level care. HIV and AIDS care and treatment services in
Tanzania were approved by the government in October
2003 under the coordination of the National AIDS
Control Programme (NACP), and ART roll-out began
in October 2004. All facilities provide ART free of
charge, and during the time of the study, there were
1,100 facilities nationwide providing ART. The target was
to provide ART to 440,000 eligible patients by the end of
2010, but only 244,148 (55%) patients had begun ART by
July 2010. During the period of this evaluation, patients
were eligible for first-line ART if they were HIV-infected,
understood the implications of therapy, and fell into one
of these three categories: patients in WHO clinical stage
IV, patients in WHO clinical stage III with CD4 count less
than 350 cells/dl, or all patients with CD4 count less than
200 cells/dl regardless of clinical criteria [12]. All patients
starting first-line ART in Tanzania are registered and
followed-up clinically and using laboratory parameters.
Normally ART patients attend clinics monthly for drug
refills and continued medical check-up. A standard-
ized national patient monitoring system, which is either
paper-based or electronic, is in use at all facilities. The re-
ports are produced quarterly through ART and pre-ART
registers.
Sampling
All facilities providing HIV and AIDS care and treatment
services were eligible for this survey. We constructed a
national sample of facilities from 17 of the 21 regions in
mainland Tanzania. We purposefully selected 35 CTCs
to represent higher-level facilities (referral or regional
hospitals) and lower-level facilities (district hospitals or
health centres) from each region to ensure representation
of different administrative levels. Our sample included all
four referral hospitals, which are distributed across the
country’s mainland. In Dar es Salaam Region, we sampled
three facilities to account for the density of ART patients.
We excluded private facilities because they are few in
number, unevenly distributed, and their reporting to the
central system has not been well established.
Using the WHO sampling guidance [13], we calculated
minimum/finite sample sizes for each EWI, based on
number of eligible patients (patients initiated on ART) for
each study indicator in 2010, the year prior to the survey.
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We chose a starting point from a list of charts based on
our EWI sample start date (January 1, 2010) and then
consecutively sampled charts until we reached minimum
sample sizes required to achieve a 95% confidence interval
of ± 7% [13]. Health care providers (HCPs) from the sam-
pled facilities conducted the data abstraction for HIVDR
EWIs. This approach aimed to build local capacities of fa-
cility staffs to be able to assess the programmatic factors
associated with HIVDR using their own data. HCPs only
included the charts of adult patients (age ≥ 15 years) who
initiated ART at their respective facility. They excluded
files belonging to patients who transferred in while on
ART from another facility after January 2010 in order
to avoid double counting had they also been sampled
from the facility where they initiated ART. Patients
who transferred out (TOs) of the study facilities were
eligible for analysis of indicator 1a, regardless of
transfer out dates. However, the TOs were excluded from
analyses of indicators 2 and 3a only if the transfer out date
was during the study period and of indicator 5b if the
transfer out date was before the first scheduled appoint-
ment after ART initiation.
Measurement
We gathered survey data using specially designated EWI
data abstraction tools. However, our selection of these
particular four indicators was based on routinely col-
lected data from NACP’s existing PMS. The four EWIs
for which we abstracted data were:
EWI 1a: Percentage of [adult] patients initiating ART at
the site during a selected time period who are initially
prescribed, or who initially pick up from the pharmacy,
an appropriate first-line ART regimen. We determined
if patients were initiated on appropriate first-line
regimen as per national guidelines and WHO
recommendations [12,14].
EWI 2: Percentage of patients initiating ART at the site
in a selected time period who are lost to follow-up
(LTFU) during the 12 months after starting ART. We
defined LTFU as a patient’s failure to attend the clinic
for 90 consecutive days (three months) following their
last visit, which is NACP’s and WHO’s standard
definition.
EWI 3a: Percentage of adult patients initiating ART at
the site during a selected time period who are taking an
appropriate first-line ART regimen 12 months later.
Being on first-line therapy included all mutual drug
substitutions and combinations within this regimen
category.
EWI 5b: Percentage of patients initiating ART at the
site during a selected time period who attended all
clinic appointments on time during the first 12 months
of ART. In keeping with the WHO definition, we
defined missing a clinic appointment as failing to
appear on the same day or within seven days of the
expected or scheduled clinic consultation date.
Two to three HCPs from each facility received training
on nationally validated data abstraction techniques using
facility-held care and treatment patient cards (CTC2).
The National HIVDR Technical Working Group provided
on-site mentorship and supportive supervision during data
abstraction to ensure that the tools were filled correctly.
Mentors and supervisors verified the data in completed
tools. They also administered structured questionnaires to
HCPs to collect information on programmatic factors such
as facility maturity (number of months providing ART ser-
vices), average hours clinics are open per day, average time
patients spend in the clinic (defined as total time spent at
the clinic, cumulatively in all departments, while waiting
for and receiving services), and other characteristics in
order to understand facility-level determinants of EWI
performance.
Analysis
Based on WHO guidance and sampling methods de-
scribed in these referenced documents [10,12,14], we
calculated that 3,608 charts would need to be abstracted
to have enough power to achieve ± 7% precision, 95% of
the time. We uploaded the abstracted patient informa-
tion into WHO HIVResNet excel-based tool [13] to de-
termine the facility-level weighted averages of EWI
performance. We assessed national performance for each
EWI by comparing the proportion of clinics that met
WHO criteria for each indicator. The WHO’s set targets
are 100% for EWI 1a, ≤ 20% for EWI 2, ≥ 70% for EWI
3a and ≥ 80% for EWI 5b. We aggregated facility-level
data and computed the proportion of facilities that
met the WHO EWI targets by various facility charac-
teristics. We analyzed the association between meet-
ing WHO EWIs and facility characteristics using Fisher’s
Exact Test in Stata v. 11 (Stata Corporation, College
Station, Texas, USA).
Ethical considerations
The HIVDR monitoring strategy in Tanzania, which in-
cludes EWIs, received ethical approval from Tanzania’s
National Institute for Medical Research’s (NIMR) Inde-
pendent Review Board in 2008 (Ref No NIMR/HQ/R.89/
Vol. IX.746). The analysis presented in this report is based
on secondary analyses of unlinked data; no contact with
human subjects occurred.
Results
We invited 35 facilities to participate in the survey, and
all agreed. The 35 facilities included 28 public and 7
faith-based facilities; 4 referral hospitals, 17 non-referral
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hospitals and 14 health centers; and 20 urban, 6 semi-
urban and 9 rural facilities. During 2010, a total of
13,466 adult patients began ART at these facilities; we
abstracted data from 3,608 (27%) charts. All facilities
adhered to the national ART management guidelines re-
garding eligibility for ART initiation. Six facilities had been
providing ART services for longer than five years while 14
had been in operation for less than three years (Table 1).
Of the 3,608 charts we reviewed from sampled facil-
ities, the weighted national average was 100% for EWI
1a, 26% (95% CI 25–26) for EWI 2, 54% (95% CI 53–54)
for EWI 3a, and 38% (95% CI 37–38) for EWI 5b
(Table 1). Of the 35 clinics, all met the WHO target for
EWI 1a, 17 clinics (49%) for EWI 2, 10 clinics (29%) for
EWI 3a and 1 clinic (3%) for EWI 5b (Table 2). None of
the clinics met all four EWI targets.
Twenty-nine (83%) ART facilities were operating their
clinics for at least eight hours per day. Patients at 6 (17%)
facilities travelled an average of less than 10 kilometers,
whereas those at 16 (46%) facilities travelled over 30 kilo-
meters on average to attend the clinic. At 14 (40%) facilities
the average time patients spent in the clinic (which in-
cluded wait time and time spent with providers) was less
than 60 minutes, and at 6 (17%) it was over 180 minutes.
Thirty (86%) facilities had no supplementary ART dispens-
ing locations; only two (6%) ART facilities provided both
refill sites and outreach services for ART. Twenty-five
(71%) facilities provided home-based services.
Facilities that met EWI 2 and 3a were more likely to
have their patients spend more than 180 minutes on
average in the clinic (p = 0.011 and 0.007, respectively),
Table 3. The only facility that met EWI 5b was a faith-
based urban referral hospital operating for less than
8 hours per day open.
Discussion
We found that all surveyed facilities had 100% of pa-
tients initiated on appropriate first-line ART regimens
Table 1 Weighted averages of HIV drug resistance EWI performance from 35 HIV care and treatment facilities,
aggregated by programmatic characteristics, Tanzania, 2010
























on ART in 2010
% % (95% CI) % (95% CI) % (95% CI)
National average
performance on EWIs
35 (100) 13,466 100 26 (25–26) 54 (53–54) 38 (37–38)
Facility administrative level
Referral hospitals 4 (11) 2346 100 25 (24–26) 53 (52–55) 54 (53–55)
Non-referral hospitals 17 (49) 8512 100 22 (21–23) 56 (55–56) 37 (36–37)
Health centers 14 (40) 2608 100 32 (30–33) 51 (49–52) 31 (30–32)
Facility geographical locality
Urban 20 (57) 11,604 100 22 (22–23) 56 (55–56) 40 (40–41)
Semi-urban 6 (17) 601 100 43 (41–46) 39 (37–41) 29 (28–30)
Rural 9 (26) 1261 100 27 (26–28) 55 (54–56) 33 (32–34)
Facility ownership
Public 28 (80) 9661 100 24 (23–25) 54 (53–55) 34 (33–34)
Faith-based 7 (20) 3805 100 30 (29–31) 53 (52–54) 50 (49–51)
Facility maturity (years providing ART services)
> 5 6 (17) 4684 100 18 (17–19) 61 (60–62) 47 (46–48)
3-5 15 (43) 6174 100 25 (24–26) 52 (51–53) 37 (37–38)
< 3 14 (40) 2608 100 32 (30–33) 51 (49–52) 31 (30–32)
Median: 4 years IQR: 2–5 years
IQR interquartile range.
EWI 1a, % of adult patients initiating ART at the site who are initially prescribed, or who initially pick up from the pharmacy, an appropriate first-line ART regimen.
EWI 2, % of patients initiating ART at the site who are lost to follow-up (LTFU) 12 months after ART initiation.
EWI 3a, % of adult patients initiating ART at the site who are taking an appropriate first-line ART regimen 12 months later.
EWI 5b, % of patients initiating ART at the site who attended all scheduled or expected clinical consultations on time during the first 12 months.
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(EWI 1a). Meeting EWI 1a is a critical success because
initiating patients on a mixture of therapies would a) com-
plicate initiation protocols and require routine genotyping
at baseline, which is not currently viable in Tanzania;
b) tap into usable therapies that should be conserved
for patients who fail first-line treatment; c) preclude the
system from monitoring patients who fail first-line and
must be switched to second-line regimens, a crucial indi-
cator for detecting resistance.
On the other hand, we found that none of the facilities
surveyed met all four WHO EWI targets, and only one
facility met EWI 5b (ART clinic appointment keeping
during the first 12 months of ART). These results are
very concerning, as missing even a few doses - particularly
during the first six months of therapy when viral loads are
high - can lead to treatment failure and drug resistance
[2,15,16]. A WHO report found that among 27 African
countries surveyed, less than half of the clinics met this
target, and globally, less than three fifths of the clinics met
EWI 5b [5].
Anecdotally, pharmacy record keeping in Tanzania
is inconsistent, therefore missing appointments is the
next best proxy for estimating treatment interruption
[5]. It is possible, however, that some patients are
missing ART clinic appointments but still picking up
their antiretrovirals at the pharmacy, so we cannot
conclusively say that treatment interruption is occur-
ring at this magnitude. Nevertheless, the results for
EWI 5b are alarming. Furthermore, WHO's recently
harmonized set of early warning indicators no longer
includes EWI 5 [17], which means appointment keep-
ing will no longer be a proxy for ART adherence and
possible drug failure.
We also found that facilities whose patients spent the
most time in the clinic (more than 3 hours, cumulatively
in all departments including wait time), were more likely
Table 2 Proportion of ART facilities that meet WHO EWI targets, aggregated by programmatic characteristics,
Tanzania, 2010
Programatic characteristics HIVDR early warning indicators (EWIs)
EWI 1a, ART
prescribing practices
EWI 2, patients LTFU
at 12 months
EWI 3a, retention on 1st
line ART at 12 months
EWI 5b, clinic appointment
keeping in first 12 months
WHO target: 100% WHO target: ≤ 20% WHO target: ≥ 70% WHO target: ≥ 80%
Frequency n (%) n (%) n (%) n (%)
National average
performance on EWIs
(N = 35) 35 (100) 17 (49) 10 (29) 1 (3)
Facility administrative level
Referral hospitals 4 4 (100) 2 (50) 0 (0) 1 (25)
Non-referral hospitals 17 17 (100) 7 (41) 5 (29) 0 (0)
Health centers 14 14 (100) 8 (57) 5 (36) 0 (0)
p = 0.793 p = 0.512 p = 0.114
Facility locality
Urban 20 20 (100) 11 (55) 5 (25) 1 (5)
Semi-urban 6 6 (100) 2 (33) 1 (17) 0 (0)
Rural 9 9 (100) 4 (44) 4 (44) 0 (0)
p = 0.727 p = 0.582 p = 1.000
Facility ownership type
Public 28 28 (100) 13 (46) 8 (29) 0 (0)
Faith-based 7 7 (100) 4 (57) 2 (29) 1 (14)
p = 0.691 p = 1.000 p = 0.200
Facility maturity (years providing ART services)
> 5 6 6 (100) 4 (67) 2 (33) 1 (17)
3-5 15 15 (100) 5 (33) 3 (20) 0 (0)
< 3 14 14 (100) 8 (57) 5 (36) 0 (0)
p = 0.324 p = 0.611 p = 0.171
EWI 1a, % of adult patients initiating ART at the site who are initially prescribed, or who initially pick up from the pharmacy, an appropriate first-line ART regimen.
EWI 2, % of patients initiating ART at the site who are lost to follow-up (LTFU) 12 months after ART initiation.
EWI 3a, % of adult patients initiating ART at the site who are taking an appropriate first-line ART regimen 12 months later.
EWI 5b, % of patients initiating ART at the site who attended all scheduled or expected clinical consultations on time during the first 12 months.
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(without controlling for clinics’ ART cohorts sizes) to
fulfill EWI 2 (LTFU 12 months after ART initiation) and
EWI 3a (retention on first-line ART at 12 months) than
others. Since we are not able to distinguish wait time
from time spent with providers, we have two possible
explanations. If longer time spent in the clinic is, in fact,
due to more patient-provider contact time, there is a
sizeable body of literature on patient satisfaction relative
to time spent with provider [18,19], and we speculate
that greater patient satisfaction may lead to lower rates
of LTFU. We also theorize that patients who spend more
time with their providers may understand and adhere to
their regimen better, leading to improved retention on
first-line regimens. Conversely, if longer visits were due
to greater wait times, research shows that patient satisfac-
tion may be high even when wait times are long [20,21].
Furthermore, it is plausible that the association between
longer wait times and higher EWI performance is con-
founded by higher quality services at some facilities.
Hypothetically, patients may be willing to wait longer
at facilities they consider higher quality (with more
skilled providers and better diagnostic equipment), while
these facilities are also more likely to perform higher in
EWIs. Nonetheless, the association between time spent
in the clinic and performance in EWI 2 and 3a should
be interpreted with caution, as measurement error and
respondent bias may be a factor. If providers overesti-
mated the average time they spend with patients, we
would expect to see a smaller effect size after taking this
into account.
We were not successful in identifying many significant
predictors of high EWI performance. Referral hospitals





LTFU at 12 months
EWI 3a, retention on 1st
line ART at 12 months
EWI 5b, Clinic appointment
keeping in first 12 months
WHO target: 100% WHO target: ≤ 20% WHO target: ≥ 70% WHO target: ≥ 80%
Frequency n (%) n (%) n (%) n (%)
Average opening time (hours)
Clinic & pharmacy: ≥ 8 hrs 29 29 (100) 16 (55) 10 (35) 0 (0)
Clinic & pharmacy: < 8 hrs 6 6 (100) 1 (17) 0 (0) 1 (17)
p = 0.177 p = 0.640 p = 0.171
Average distance (kilometers, km) travelled by patient
≥ 51 km 10 10 (100) 5 (50) 3 (30) 1 (10)
21-50 km 10 10 (100) 5 (50) 3 (30) 0 (0)
11-20 km 8 8 (100) 6 (75) 3 (38) 0 (0)
≤ 10 km 7 7 (100) 1 (14) 1 (14) 0 (0)
p = 0.162 p = 0.885 p = 1.000
Average time (minutes) patient spent at the Clinic
>180 minutes 6 6 (100) 6 (100) 5 (83) 0 (0)
60-180 minutes 15 15 (100) 7 (47) 3 (20) 1 (7)
< 60 minutes 14 14 (100) 4 (29) 2 (14) 0 (0)
p = 0.011* p = 0.007* p = 1.000
Supplementary ART dispensing locations
Refill, outreach or both 5 5 (100) 2 (40) 2 (40) 0 (0)
Neither 30 30 (100) 15 (50) 8 (27) 1 (3)
p = 1.000 p = 0.610 p = 1.000
Home based services
Yes 25 25 (100) 13 (52) 6 (24) 1 (4)
No 10 10 (100) 4 (40) 4 (40) 0 (0)
p = 0.711 p = 0.421 p = 1.000
*Statistically significant.
EWI 1a, % of adult patients initiating ART at the site* who are initially prescribed, or who initially pick up from the pharmacy, an appropriate first-line ART regimen.
EWI 2, % of patients initiating ART at the site* who are lost to follow-up (LTFU) 12 months after ART initiation.
EWI 3a, % of adult patients initiating ART at the site* who are taking an appropriate first-line ART regimen 12 months later.
EWI 5b, % of patients initiating ART at the site* who attended all scheduled or expected clinical consultations on time during the first 12 months.
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did not perform better than lower level facilities with re-
gard to patient retention on first-line ART (EWI 3a) as
we expected. Perhaps this is because more experienced
clinicians in referral hospitals may be better equipped to
recognize patients who are failing their first-line regimen
and move them to second-line therapy. We also ex-
pected that facilities with supplemental ART dispensing
locations (such as refill sites and outreach services) and
home based care would be more successful with LTFU
and appointment keeping, but this was not the case. It
is possible that with a few sampled facilities and only
some facilities providing outreach services, that we did
not have sufficient power to detect this difference. Lastly,
we anticipated facilities whose patients walk longer aver-
age distances would perform worse overall, but perhaps
some patients choose to travel to more distal facilities to
avoid the stigma of receiving treatment near their homes.
Our study is subject to several limitations. It is the first
assessment of its kind undertaken in Tanzania, and in fu-
ture studies, we hope to obtain better measures for treat-
ment interruption, as well as more robust measures of
facility characteristics, such as patient visit times, to better
understand how patients spending more time in the clinic
results in less attrition and greater retention on first-line
ART. Given the human resource shortages Tanzania faces,
we are not suggesting that providers should spend more
time with patients, but that understanding the factors that
contribute to more efficient clinic visits is crucial for bal-
ancing human resource constraints with providing both
effective and quality care. Secondly, our sample was not
perfectly representative of all ART facilities in the nation,
and we plan to extend subsequent surveys to areas not
covered in this initial survey, including the private facil-
ities, as well as to randomly sample lower-level facilities to
avoid selection bias. Finally, there are inherent limitations
in the survey methods we employed. We were unable to
develop data on the WHO HIVDR EWIs that cannot
be obtained from routine patient monitoring, which
we plan to address with additional special surveys in
our next monitoring round. Additionally, we plan in
the future to triangulate EWI data, like those collected
in this study, with HIVDR threshold and monitoring sur-
veys, both of which are undergoing development. Despite
these limitations, we believe that our data point out suc-
cesses (initiating ART) and where our system needs im-
mediate improvements (attrition, retention on first-line
ART and clinic appointment keeping). It is with periodic
surveys such as this that ART services in Tanzania can
be improved to provide the best care and treatment for
our patients.
Conclusion
In conclusion, Tanzania performed very well in EWI 1a,
ART prescribing practices, but its performance in the
other three EWIs fell far short of the WHO targets. This
study provides a baseline for future monitoring of EWIs
in Tanzania. It also conveys lessons learned for surveys
that aim to identify practices contributing to the emer-
gence or prevention of HIVDR. EWIs are a quicker as-
sessment technique and they are crucial for tracking
HIVDR in resource-limited settings where individual-
level monitoring is not feasible. In addition to the na-
tional monitoring of EWIs, clinics should be empowered
to use their own data to track EWIs more routinely at a
facility level in order to address problems or gaps in a
timely manner. With better understanding of the pro-
grammatic factors that contribute to decreased HIV
drug resistance, we may continue to improve the quality
of ART services provided for Tanzanians living with HIV
and AIDS, and ultimately, the quality of their lives.
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